{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:34:55Z","timestamp":1761755695768,"version":"build-2065373602"},"reference-count":28,"publisher":"Wiley","issue":"6b","license":[{"start":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T00:00:00Z","timestamp":1327881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (case series)<\/jats:p>\n                    <jats:p>Level of Evidence\u20034<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>In bladder\u2010sparing approach incorporating TURBT and chemoradiotherapy (CRT) to MIBC, patients who clinically achieve complete response to induction CRT enjoy favourable prognosis and quality of life with preserved functioning bladder, whereas those with persisting disease have poor prognosis despite salvage radical cystectomy. Risk factors for cancer death among the non\u2010responders remain fully unknown. The current study showed that survival of the non\u2010responders is clearly stratified into low\u2010 and high\u2010risk groups based on pathology of cystectomy specimens; 5\u2010yr CSS rates for low\u2010 (pTO\u20102pNO) and high\u2010risk (pT3\u20104a or pN+) patients were 85% and 20%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To stratify patients with a clinical non\u2010complete response (CR) after induction chemoradiotherapy (CRT) according to their risk of death from cancer, based on pathology of cystectomy specimens.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>From 1997 to 2009, 170 patients with cT2\u20104aN0M0 bladder cancer underwent transurethral resection followed by induction CRT (40\u2003Gy with cisplatin). Clinical response was evaluated 4\u20136 weeks after completion of CRT.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Patients who met partial cystectomy (PC) criteria underwent PC plus pelvic lymph node dissection for bladder preservation. Otherwise, radical cystectomy (RC) was recommended.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>PC criteria were unifocal tumours, intact bladder neck and trigone, and CR (defined as no evidence of residual disease) or minimal amounts of residual non\u2010muscle\u2010invasive bladder cancer after induction CRT.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Pathological variables associated with cancer death were analysed in patients who underwent PC or RC using a multivariate Cox proportional hazard model.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>\n                            Of 170 patients, 81 (48%) achieved a CR and 62 (36%) met the PC criteria. After CRT, 122 patients (72%) ultimately underwent PC (\n                            <jats:italic>n<\/jats:italic>\n                            = 44, 26%) or RC (\n                            <jats:italic>n<\/jats:italic>\n                            = 78, 46%).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The 5\u2010year cancer\u2010specific survival (CSS) rate was 96% for the patients with a CR and 50% for patients with non\u2010CR (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.001, median follow\u2010up for survivors: 48 months).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            In the 122 patients who underwent cystectomy, pT3\u20104a (hazard ratio [HR] 8.3 versus pTO\u20102,\n                            <jats:italic>P<\/jats:italic>\n                            \u2003&lt;\u20030.001) and pN+ (HR 3.0 versus pNO,\n                            <jats:italic>P<\/jats:italic>\n                            \u2003=\u20030.037) were identified as significant and independent risk factors among variables including pT stage, lymph node yield at cystectomy, pN stage, and Iymphovascular invasion. A similar result was obtained through analysis of a sub\u2010cohort of 69 patients with non\u2010CR.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Patients with non\u2010CR were stratified according to their risk factors into low\u2010 (pT0\u20102pN0, 5\u2010year CSS rate 85%) and high\u2010risk (pT3\u20104a or pN+, 5\u2010year CSS rate 20%) groups.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>In CRT\u2010based bladder\u2010sparing approaches, patients with a clinical non\u2010CR after induction CRT can be stratified into low\u2010 and high\u2010risk groups for death from cancer based on pathology of cystectomy specimens. Patients at high risk are potential candidates for intensive adjuvant therapy including clinical trials.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2011.10874.x","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T13:32:48Z","timestamp":1327930368000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pathology\u2010based risk stratification of muscle\u2010invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder\u2010sparing approaches"],"prefix":"10.1111","volume":"110","author":[{"given":"Fumitaka","family":"Koga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Numao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minato","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun\u2010ichiro","family":"Ishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,30]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22556"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.89"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1298"},{"issue":"1","key":"e_1_2_7_5_2","first-page":"CD002079","article-title":"Surgery versus radiotherapy for muscle invasive bladder cancer","author":"Shelley MD","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00718-1"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.027"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01650-3"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/jama.1987.03400070069037","article-title":"Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery","volume":"258","author":"Shipley WU","year":"1987","journal-title":"JAMA"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90306-G"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.01.054"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66440-3"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.666"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000093721.23249.c3"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.11.2901"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00579-8"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08297.x"},{"key":"e_1_2_7_18_2","article-title":"Selective bladder\u2010sparing protocol consisting of induction low\u2010dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle\u2010invasive bladder cancer: oncological outcomes of the initial 46 patients","author":"Koga F","year":"2011","journal-title":"BJU Int"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.03.017"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.06.111"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2009.02366.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.1"},{"volume-title":"Classification of Malignant Tumours","year":"2002","author":"Sobin LH","key":"e_1_2_7_23_2"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-630"},{"key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"LBA4518","DOI":"10.1200\/jco.2010.28.18_suppl.lba4518","article-title":"Randomized phase III trial comparing adjuvant paclitaxel\/gemcitabine\/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99\/01 study","volume":"28","author":"Paz\u2010Ares LG","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000135530.59860.7d"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00322-3"},{"key":"e_1_2_7_28_2","first-page":"4757","article-title":"The invasive front of carcinomas. The most important area for tumour prognosis?","volume":"18","author":"Bryne M","year":"1998","journal-title":"Anticancer Res"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000110541.62972.08"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10874.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10874.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:31:20Z","timestamp":1761755480000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10874.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,30]]},"references-count":28,"journal-issue":{"issue":"6b","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10874.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10874.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2012,1,30]]},"assertion":[{"value":"2012-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}